CRLs
Unlocking Access: Navigating Pharma’s Regulatory Crossroads – Recent Updates (2025)
pharmaceutical regulation; market access; drug pricing; FDA transparency; biosimilars; executive actions; market access strategy; drug importation; CRLs; patient access
FDA Releases Second Batch of Complete Response Letters, Moves to Real-Time Public Disclosure
FDA; Complete Response Letters; CRLs; real-time publishing; drug approvals; transparency; regulatory disclosure